Asparagine auxotrophy, which forms the basis for treatment of leukemia with L-asparaginase, (L-asp) has been shown in animal tumor cells to be related to the loss of expression of the enzyme Asparagine Synthetase (ASNS) (EC 6.3.5.4). 1 The extension of this concept to L-asp sensitivity in clinical cases of acute lymphoblastic leukaemia (ALL) has recently been challenged by the results of ASNS mRNA measurements in patients with t(12;21) translocations. The methodology favoured for measuring ASNS expression has been quantitative real-time PCR (qRT-PCR). [2] [3] [4] This technique presents numerous difficulties in application, particularly in the normalization of results and the use of reference genes, as recently reviewed. 5 Indeed, using variations of the method, a number of workers have drawn differing conclusions from studies of leukemic cells in short-term culture and in marrow specimens. [2] [3] [4] In addition, an examination of the mRNA and genomic sequences for ASNS shows additional factors that could contribute to the uncertainty. We therefore propose a simplified method for this assay in which these features are taken into account.
In the first place, there is the probability of inaccuracy due to a high degree of contamination with genomic DNA. This is a particular problem with small biological samples of varied nucleic acid content and in which there may only be a few copies of message. 5 To preferentially amplify mRNA, primers are selected that bridge intronic sequences or are located across a splice junction. However, genomic DNA contains processed pseudogenes (PCgs), which lack introns ( Figure 1a ) and can be amplified as a product indistinguishable from cDNA ( Figure 1b,  lanes 1-3) . This is the case for ASNS (3 PCgs) but even more so for the commonly used genes of reference, GAPDH (B20 PCgs) and b-actin (B9 PCgs). With large numbers of PCgs, as in the case of reference genes, design of specific primers or of specific probe sequences is extremely difficult and published methods have not usually accomplished this. Furthermore, if an amplification step is used before microarray analysis, the same problem can occur. It is possible prior to qRT-PCR analysis to remove genomic DNA by DNaseI treatment, but this results in a loss of mRNA ( Figure 1b , lanes 8-9 and 17-18) even when the recombinant enzyme DNA-freet (Ambion) is used.
A second factor that must be taken into account with ASNS is the expression of at least three variant transcripts with alternative initial exons ( Figure 2 ). Since it is not known whether differential expression may occur under varying circumstance, primers must include all transcripts. In recent studies by Stams et al 2 and Irino et al 3 the primers would amplify specifically from the consensus region of the three transcript variants. However, BLAST analysis against the human genome sequence indicates a significant potential for amplification from the PCg (on Chr18). The fragment generated is of the same size as that produced from mRNA and has almost exact homology in the region to which the probe anneals. In addition, in both cases expression levels where normalized against GAPDH, with more than 20 PCgs. Again, the primers used would generate a product capable of probe hybridization. To ensure that amplification is exclusively from mRNA and not PCg contamination a noreverse transcription (RT) control should be used with every sample. Alternatively, Krejci recently employed a technique that circumvented the PCg problem by careful design of ASNS primers and use of b2-microglobin. 4 However, as b2-microglobin has a variable expression pattern it has been suggested that it may not be effective as a reference gene. 6 We therefore demonstrate the use of a recently published method that permits the use of common reference genes and takes into account the issues raised. 7 The technique first uses a 'universal' primer to initiate RT. One end of this primer anneals to the polyA tail and during the RT process, a unique sequence tag incorporated in the primer is added to the cDNA. Subsequent amplification with the gene-specific primer and a primer compatible to the unique tag results in exclusive amplification of cDNA even in the presence of contaminating gDNA. 7 In contrast to the b-actin primers, the GAPDH primers shown were designed for amplification in conjunction with the 'universal' primer ( Figure 1b) . The identical sample set was analyzed with each primer pair and two significant factors are apparent. First, the universal system amplifies exclusively from cDNA; no product is generated from the no-RT control (Figure 1b, contrast lanes 1-5 and 10-14) . Second, the loss of signal is due to reduction of RNA in the sample after DNaseI treatment. As shown, the GAPDH primers amplify exclusively from cDNA, yet signal is lost after DNaseI treatment (Figure 1b,  lanes 17-18) .
The effectiveness of the universal system is demonstrated using cDNA extracted from a variety of cell lines (Figure 3) . Two of the lines (CRL-1873 and CRL-1929) are known to be asparagine auxotrophs and lack of expression is associated with methylation of the promoter region. 8 Expression levels are undetectable in comparison to the measurements made from a variety of asparagine prototrophic cell lines. The assay used in this report is therefore in agreement with the results for this and other studies concerning ASNS expression in these cell lines. The preliminary data indicates that this system will work in vivo with ASNS as it has previously been shown to do with GSTP1. 7 Further optimization will ensure that this method will provide a robust, sensitive and accurate means of ASNS measurement. This technique requiring as it does, a minimal number of steps, can therefore be used to amplify exclusively from the mRNA of ASNS and the reference gene from cDNA without requiring DNaseI treatment. 
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